Introduction
Emerging clinical data is driving momentum across a wide spectrum of therapeutic areas. From metabolic liver disease and neuro-ophthalmology to inflammatory skin conditions, the latest Phase 2 trial readouts and translational breakthroughs are pointing toward safer, more effective treatment pathways. These updates reflect how companies are leveraging imaging tools, extracellular vesicle platforms, and targeted cytokine inhibition to redefine patient care.
Akero and HistoIndex Present New NASH Analyses from the HARMONY Trial
At EASL 2025, Akero Therapeutics and HistoIndex revealed new imaging and histological insights from Akero’s Phase 2b HARMONY trial evaluating efruxifermin (EFX) for nonalcoholic steatohepatitis (NASH).
The analysis, powered by HistoIndex’s AI-driven imaging platform, demonstrated:
- Significant improvements in fibrosis regression with EFX compared to placebo.
- Enhanced resolution of steatohepatitis in responders.
- Greater precision in assessing tissue remodeling using second harmonic generation microscopy.
These results support EFX as a potential disease-modifying therapy for NASH and highlight the role of advanced imaging in driving accurate liver disease assessment. Akero, HistoIndex reveal new Phase 2b HARMONY trial analyses at EASL 2025
Nurexone Advances Vision Restoration Program at ARVO 2025
Nurexone Biologic presented compelling preclinical data at ARVO 2025, highlighting the company’s ExoTherapy platform in promoting vision restoration after optic nerve injury. The therapy leverages extracellular vesicles (EVs) to deliver regenerative signals directly to damaged neurons.
Highlights from the presentation include:
- Improved axonal regeneration in rodent models with partial optic nerve transection.
- Evidence of visual function recovery in treated animals.
- A novel, non-invasive approach with scalable potential for other central nervous system injuries.
Nurexone’s EV-based therapy represents a promising frontier in neuro-ophthalmology, particularly for irreversible vision loss conditions. Nurexone advances vision restoration at ARVO 2025
Soquelitinib Demonstrates Efficacy in Atopic Dermatitis Trial
New clinical trial results for soquelitinib, a selective IL-2-inducible T-cell kinase (ITK) inhibitor, show strong efficacy in patients with moderate-to-severe atopic dermatitis. The treatment works by modulating T-cell signaling pathways implicated in chronic skin inflammation.
Study data revealed:
- Meaningful reductions in eczema severity scores.
- Improvements in itch and sleep quality within weeks.
- Favorable safety profile and oral dosing convenience.
Soquelitinib could offer an effective, targeted option for patients unresponsive to conventional biologics or topical steroids.Soquelitinib shows promise in atopic dermatitis trial
Conclusion
These recent trial findings in NASH, vision restoration, and dermatology demonstrate how precision-driven science is transforming care in previously hard-to-treat diseases. As imaging, exosome biology, and cytokine targeting evolve, the therapeutic potential across disciplines grows stronger. Follow more clinical updates at Clinical Trial Vanguard.
